Azitra Raises $10.5 M, Adds MD Anderson Site, Secures ATR-12 Patent
Azitra added MD Anderson Cancer Center as a site for its Phase 1/2 ATR-04 EGFRi rash trial and launched proprietary filaggrin protein and peptide programs for cosmetic markets. The company secured a U.S. patent for ATR-12, raised $10.5 million in private placement financing (with $20.9 million in warrant proceeds), and held $10.1 million in cash.
1. Q1 2026 Business Highlights
In Q1 2026, Azitra broadened its Phase 1/2 ATR-04 trial by adding MD Anderson Cancer Center and initiated proprietary filaggrin protein and peptide programs targeting cosmetic and cosmeceutical markets. The company also secured a U.S. patent for lead candidate ATR-12 and priced a private placement financing of $10.5 million with up to $20.9 million in warrant proceeds.
2. Pipeline Achievements and Upcoming Milestones
Key upcoming milestones include mid-2026 results from synthesized filaggrin ingredient studies for the ATR-COSF consumer initiative and a human cosmetic application study in Q3 2026. The ATR-12 Phase 1b trial topline data is anticipated in H2 2026, ATR-04 Phase 1/2 first cohort data is expected in H2 2026, and ATR-01 IND-enabling studies continue in 2026.
3. Financial Results for Q1 2026
For the quarter ended March 31, 2026, research and development expenses rose to $1.6 million from $1.3 million year-over-year, general and administrative expenses increased to $2.4 million from $1.9 million, and net loss widened to $3.9 million from $3.1 million. As of quarter end, the balance sheet held $10.1 million in cash and cash equivalents.